Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 15.4% – Here’s What Happened

Ernexa Therapeutics Inc. (NASDAQ:ERNA) shares were down 15.4% on Monday . The company traded as low as $5.33 and last traded at $5.43. 248,372 shares changed hands during trading, a decline of 82% from the average session volume of 1,359,927 shares. The stock had previously closed at $6.42.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Wall Street Zen upgraded Ernexa Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Friday. Zacks Research upgraded Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. Finally, Brookline Capital Markets began coverage on shares of Ernexa Therapeutics in a report on Thursday, May 7th. They set a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $30.00.

Ernexa Therapeutics Stock Performance

The firm has a market cap of $5.19 million, a P/E ratio of -0.17 and a beta of 2.50. The firm’s fifty day simple moving average is $7.90 and its 200 day simple moving average is $11.20.

Ernexa Therapeutics (NASDAQ:ERNA) last posted its earnings results on Monday, May 11th. The company reported ($6.95) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). On average, equities research analysts predict that Ernexa Therapeutics Inc. will post -18.02 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 70.55% of the stock is currently owned by hedge funds and other institutional investors.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.